

Xolair SAA - Resources - Auto injector video - HCP

Prescribing information

Image



Image



Instructions for using the Xolair autoinjector

INSTRUCTIONS FOR USE OF XOLAIR® (omalizumab) PRE-FILLED PEN/AUTOINJECTOR

This video is intended for patients who have been prescribed Xolair.

Xolair is used for the treatment of:

Allergic asthma: This medicine is used to prevent asthma from getting worse by controlling symptoms of severe allergic asthma in adults, adolescents and children (6 years of age and older) who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high-dose steroid inhalers and beta-agonist inhalers.

Chronic spontaneous urticaria (CSU): This medicine is used to treat CSU in adults and adolescents (12 years of age and older) who are already receiving antihistamines but whose CSU symptoms are not well controlled by these medicines.

Reporting of side effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This included any possible side effects not listed in the information leaflet that comes in the pack. You can report side effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of your medication.

This video has been developed and funded by Novartis Pharmaceuticals UK.



UK | September 2024 | FA-11244812



Use this video to learn how to prepare and use the Xolair autoinjector at home once you or your caregiver have been trained by your healthcare provider. You can read more about Xolair and how to use it in the <u>patient information leaflet (PIL)</u>. This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.*

*The PIL is the leaflet included in the pack with a medicine. It is written for patients and

gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

UK | March 2025 | FA-11360024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

https://www.pro.novartis.com/uk-en/medicines/respiratory/xolair/resources/autoinjector-video